Biosafety standards for working with Crimean-Congo haemorrhagic fever virus

Weidmann M[1], Avsic-Zupanc T[2], Bino S[3], Bouloy M[4], Burt F[5], Chinikar S[6], Christova I[7], Dedushaj I[8], El-Sanousi AA[9], Eladi N[10], Weber F[11], Hewson R[12], Hufert F[13], Humolli I[8], Koçak Tufan Z[14], Korukluoglu G[15], Leyssen P[16], Mirazimi A[17], Neyts J[16], Niedrig M[18], Ozkul A[19], Papa A[20], Paweska J[21], Sall AA[22], Schmaljohn C[23], Swanepoel R[24], Jansen van Vuren P[21], Uyar Y[25], Zeller H[26]

1 Institute of Aquaculture, University of Stirling, Stirling, Scotland, UK
2 Institute of Microbiology and Immunology, Medical Faculty of Ljubljana, Ljubljana, Slovenia
3 Institute of Public Health, Control of Infectious Diseases Depart Albania
4 Institut Pasteur, Bunyaviruses Molecular Genetics, Paris, France.
5 Department of Medical Microbiology and Virology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa
6 Laboratory of Arboviruses and Viral Hemorrhagic Fevers (National Ref Lab), Pasteur Institute of Iran, Tehran, Iran
7 National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
8 National Institute of Public Health in Kosovo, Pristina, Kosovo.
9 Department of Virology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
10 Department of Infectious Diseases and Clinical Microbiology, Cumhuriyet University, Faculty of Medicine, Sivas, Turkey.
11 Institute for Virology, Justus Liebig-University Giessen, Giessen, Germany
12 Public Health England, Porton Down, Wiltshire, Salisbury, UK
13 Institute of Microbiology and Virology, Brandenburg Medical School, Senftenberg, Germany.
14 Infectious Diseases and Clinical Microbiology Department, Yildirim Beyazit University, Ankara Ataturk Training and Research Hospital, Ankara, Turkey.
15 Public Health Institution of Turkey, Virology Reference and Research Laboratory, Ankara, Turkey.
16 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
17 Institue for Laboratory Medicine, Dept for Clinical Microbiology, Karolinska Institute, and Karolinska Hospital University, Stockholm, Sweden
18 Centre for Biological Threats and Special Pathogens, Highly Pathogenic Viruses, Robert Koch Institute, Berlin, Germany.
19 Ankara University, Faculty of Veterinary Medicine, Department of Virology, Ankara, Turkey.
20 Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
21 National Institute for Communicable Diseases, Johannesburg, South-Africa
22 Arbovirus unit, Pasteur Institute, Dakar, Senegal
23 US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
24 Department of Veterinary Tropical Diseases, University of Pretoria, Pretoria, South Africa
25 Department of Medical Microbiology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey
26 European Centre for Disease Prevention and Control, Stockholm, Sweden

Corresponding author

Manfred Weidmann
University of Stirling
Institute of Aquaculture
Stirling FK9 4LA
Scotland, United Kingdom

tel: +441786467873

e-mail: m.w.weidmann@stir.ac.uk

Running Title: Crimean-Congo haemorrhagic fever virus biosafety
Keywords: Crimean-Congo haemorrhagic fever virus biosafety

Word count abstract: 132 words
Word count text: 3325 words

Abstract

In countries from which Crimean-Congo haemorrhagic fever (CCHF) is absent, the causative virus CCHF virus (CCHFV) is classified as a hazard group 4 agent and handled in containment level 4. In contrast, most endemic countries out of necessity have had to perform diagnostic tests under biosafety level (BSL) 2 or 3 conditions. In particular, Turkey and several of the Balkan countries have safely processed more than 100000 samples over many years in BSL-2 laboratories. It is therefore advocated that biosafety requirements for CCHF diagnostic procedures should be revised, to allow the required tests to be performed under enhanced BSL-2 conditions with appropriate biosafety laboratory equipment and personal protective equipment used according to standardized protocols in the affected countries. Downgrading of CCHFV research work from Cl-4,BSL-4 to Cl-3 ,BSL-3 should also be considered.

Introduction

Crimean-Congo haemorrhagic fever virus (CCHFV), a member of the *Nairovirus* genus of the family *Bunyaviridae*, causes a tick-borne zoonotic infection (Crimean-Congo haemorrhagic fever (CCHF)) in parts of Africa and Eurasia [1]. CCHFV has been classified as a hazard group 4 pathogen (UK) or risk group 4 (Europe, USA, international) in countries that have promulgated biosafety regulations, and should accordingly be handled in containment level 4 (CL4, UK) or biosafety level 4 (BSL-4, Europe, USA, international) laboratories (Table 1).

Signs and symptoms after a sudden onset of disease 1–7 days post infection, progress from high grade of fever, headache, fatigue, myalgia, abdominal pain, nausea, vomiting, diarrhoea, thrombocytopenia and rash, to haemorrhages from various body sites, shock and death in severe cases. Reported mortality rates vary widely from to 2-30% across studies and endemic countries [2,3].

Apart from transmission by tick bite as a major route of infection, transmission can also occur through handling or squashing of infected ticks, and contact with the blood of viraemic animals, or blood and other body fluids of patients. Consequently, livestock farmers, abattoir and healthcare workers (HCWs) dominate the literature on reported infections. Nosocomial transmission to HCWs in close contact with patients in the acute phase have been documented throughout the endemic areas and are often linked to breaches of, or non-existent, barrier nursing techniques, or to percutaneous needlestick injuries [4].

Following the occurrence of the first recognized outbreaks of 'Crimean haemorrhagic fever' in soldiers and displaced persons exposed to ticks while sleeping outdoors in 1944 and 1945, there were similar outbreaks associated with exposure of large numbers of people to ticks in major land reclamation or resettlement schemes in parts of the former Soviet Union, culminating in an epidemic in Khazakstan in 1989 [5] [6] [7]. Subsequently, there were reports

of a series of lesser outbreaks associated with exposure of people to blood and ticks from slaughter animals imported from Africa and Asia into the Near East [8]. Further large-scale outbreaks that occurred during the late 1990s and early 2000s, involved exposure of war refugees to outdoor conditions in Kosovo, Albania, Macedonia and the Afghanistan-Pakistan border area [7,9]. Finally, an outbreak of unprecedented magnitude emerged in Turkey in 2003 with 9787 clinical and laboratory confirmed CCHF cases by 2015. This outbreak has been ascribed to an increase in the tick population triggered by climate change, altered grazing practices and prohibition of the hunting of wild hosts of ticks (Vatansever et al., 2007).

Consequently, in recent years the existing laboratory and health care facility infrastructure in south-eastern Europe and the Balkans, and especially in Turkey, had to adapt to deal with a large influx of patients and samples potentially infected with a hazard group 4 pathogen.

The purpose of this paper is to review experiences of HCWs and scientists in handling CCHF patients and CCHFV-positive materials in order to derive safe recommendations for safe laboratory processing of known or suspected CCHFV-infected samples, and particularly at which biosafety level CCHFV material and samples from CCHF patients can be handled safely. First of all we re-aphraise CCHF case fatality rates in endemic countries and in clinical cases. This is followed by a review of nosocomial infections and the most recent data from the large epidemic in Turkey, which indicate CCHFV is less easily transmitted from person to person than thought as exemplified by seroprevelance studies amongst health care workers dealing with CCHF patients, and is not transmitted in the community. We then turn to laboratory acquired infections (LAI) while handling diagnostic or research samples and revealing that most infections were due to breaches of biosafety procedures in place and that a surprising high number of these infections had a mild or self limiting course. Finally we look at inactivation procedures for diagnostic samples to then formulate our recommendations for working with

CCHFV.

Reported mortality rates and seroprevalences

Observed case fatality rates (CFR) in CCHF vary from 2-30%, and are influenced by efficiency of diagnosis, cohort size sampled, and speed of clinical intervention [1, 2]. Reported CFR include 25% from South Africa [10], 26% from Kosovo [11] and 15% from Iran and Bulgaria [12,13]. A structured epidemiological investigation in South Africa revealed that all or most infections in that country result in clinical disease (Fisher-Hoch et al., 1992). Analysis of ProMED entries on CCHF from 1998 through 2013 reveals a CFR of 13% among 3,426 cases reported from Turkey, Russia, Iran, Pakistan, and Afghanistan [2]. In South Russia the CFR has decreased from 12-16% (1953 -1967) through 1.5-2% (2006-2010) to 3.6-5.1% (2011-2013). This is possibly due to an increased use of diagnostic kits and awareness of CCHF among medical staff [3].

Following a regional epidemic in Turkey in 2003 and subsequent spread, 9787 cases with a CFR of 4.6% were recorded by the end of 2015, which represents the highest number of cases on record [14]. Studies in Turkey revealed a seroprevalence of 10%-15% in outbreak regions, with 88% of infections appearing to be subclinical [15,16]. The disease is often milder in children than in adults [17]. Additionally, the circulation of CCHFV in endemic regions of Turkey is supported by serological studies on domestic and wild animals, with antibody prevalences reflecting the feeding preferences of the *Hyalomma* tick species that transmit the virus. [18-23].

CCHFV strain AP92 has been suggested to be less virulent than other CCHFV strains [24-26]. It was initially isolated in 1975 [27], from *Rhipicephalus bursa* collected from goats in Greece and AP92-like sequences have only recently been detected in ticks in Greece, Kosovo and Albania. A CCHFV AP92 like strain was also described in human cases in Turkey but only

causing mild CCHF [24,26]. Recent data indicate a high CCHFV seroprevalence of up to 15% in some CCHF non-endemic areas of Greece (Kastoria) possibly correlated to CCHFV-AP92 transmission by *R. bursa*. This seems to be confirmed by recent data from Kosovo and Albania [11,28,29]. The serological and epidemiological data support the initial assessment that CCHFV AP92 may be less pathogenic however there are no laboratory data to confirm this.

In contrast, after 13 years the CFR in Turkey remains about 5% despite major efforts to implement protection and prevention measures as well as public health training programmes and social mobilisation [14,15,26,30].

Nosocomial CCHF infections

Nosocomial infections were recorded during the first reported outbreaks of 'Crimean haemorrhagic fever' in 1944 and 1945, and subsequently in other parts of the former Soviet Union and neighbouring countries (Hoogstraal, 1979). A more recent detailed literature review of nosocomial CCHF transmission to HCW listed 44 infections in 494 HCW contacts in 12 countries [4]. Nosocomial infections were reported from South Africa [31-35], Mauretania [36], Sudan [37], Albania [38,39], Kosovo [40], Bulgaria [41,42], Turkey [43,44], Iran [45-47], Dubai [48], Pakistan [49,50], India [51], Tajikistan [52], Kazakhstan [53] and Germany [54].

Nosocomial transmission often occurs during early illness before CCHF is recognized in the source patient, or where diagnostic laboratory capability is not available, and is usually associated with lack of, or improper use of, personal protective equipment (PPE). Once CCHF is recognized nosocomial infection tends to occur most commonly where source patients manifest severe disease, probably because they develop the highest viraemias. Recent studies confirm that when a threshold of 10^8 viral genomes per ml of blood is exceeded the disease progresses to fatal outcome [9,55].

In general there is a very low CCHFV seropositivity in HCW dealing with CCHF patients in Turkey [56,57], and data on infections in HCW in Turkey describe, an up to 33% risk of infection associated with needlestick injuries, and a 9% risk after contact with body fluids [58]. In Iran serological studies revealed a seroconversion rate of 3.8% in HCW exposed to CCHF patients. The seroconversion was 9.3% in HCW who had unprotected skin contact with body fluids and 7.1% in those who suffered percutaneous injuries [59]. A more recent study covering 9 hospitals which managed 50% of CCHF patients in Turkey from 2002-2014 found 51 HCW exposures by needlestick (62.7%), splashes (23.5%) and unidentified cause (13.7%). Only 25 of these 51 exposures led to laboratory confirmed infections and 4 deaths [60].

High compliance to and proper use of PPE can indeed minimize the risk of infection as documented in a study from the Cumhuriyet University Education and Research Hospital in Turkey, were 1284 confirmed CCHF patients were treated between 2002 and 2012. The total seropositivity for CCHFV IgG was only 0.53% in HCW in infectious disease wards which showed a high compliance to PPE of 100%, 88.6%, and 82.9% for gowns, gloves and masks [61]. This is supported by another survey of 90 HCWs from 3 hospitals in the endemic regions which found a low seropositivity rate of 1% [62].

Altogether the clinical consensus is that simple barrier nursing and PPE can provide a good measure of protection to HCW [4]. This is for example the case in the Ankara Ataturk Training and Research Hospital, were HCWs use contact protection (hand hygiene, gowns and gloves when needed). N95 masks and goggles are used only when dealing with patients with severe haemorrhagic symptoms in need of aerosol and droplet producing procedures such as aspiration and intubation. This pragmatic approach reduces full protection to the most severe cases from which nosocomial CCHFV transmission is most probable. Over the years four doctors and three nurses had contact with infected blood and body fluids of CCHF patients,

135 through needlestick injury, skin contact, contact to mucosal surfaces, and probable
136 aerosolization. All index cases were CCHFV PCR positive. The only HCW who developed
137 seroconversion intubated an unconscious patient who had suffered a seizure. She was
138 wearing gloves but no respiratory or eye protection.
139 In another incident one HCW from the Ankara hospital forgot to don goggles when performing
140 an emergency cardiopulmonary resuscitation (CPR) treatment of a severely ill CCHF patient.
141 When injecting a drug some blood squirted into her eye, which was immediately washed.
142 Neither infection nor seroconversion resulted from the incident. Furthermore, no
143 seroconversion was observed in any of the team performing the CPR without protective N95
144 masks (Z. Kocak Tufan, Turkey, personal communication).
145
146 **Laboratory acquired infections (LAI) while handling patient samples**
147 Modern diagnostic procedures usually compromise extraction of RNA from blood or other
148 tissues of patients and the performance of an RT-PCR, plus antibody tests on heat-inactivated
149 serum [57]. Culture of specimens for isolation of virus is performed less frequently.
150 Eight laboratory infections, one fatal, were recorded in Uganda during early investigations of
151 'Congo' virus in the 1960s. Where known, exposure of patients to infection occurred during
152 the handling or processing of infected mice (EAVRI Reports cited in [63]).
153 A laboratory assistant infected himself while preparing plasma from a blood sample of a CCHF
154 patient by centrifugation in 1986 in a laboratory in Rostov-na-Donu, Russia. The assistant
155 developed a full-blown CCHF clinical picture including haemorrhages but survived after
156 prolonged convalescence. A high initial CCHFV LD_{50} titer on day 1 and seroconversion were
157 demonstrated [64].
158 In South Africa, a clinical pathology laboratory technologist in a hospital in Kimberly was found

to be seropositive for CCHF in 1986, but the presence of IgG antibody could not be conclusively linked to an earlier benign illness. The technologist routinely wore a laboratory coat and disposable gloves and performed all manipulations with blood and serum in class II cabinets. She used automated haematology and clinical pathology machines. A fatal case of CCHF occurred in 2006 in a technologist in a clinical pathology laboratory in Vereeniging, South Africa, who putatively only handled blood samples from a deceased CCHF patient in order to store them in a freezer. He had signed a procedure protocol which instructed him to wear a laboratory coat and gloves, but nobody observed him storing the samples. The technologist reportedly had not tested the samples and it was never determined whether he had worn gloves, or how he was exposed to infection, but virus isolates from the source patient and the technologist had identical nucleotide sequences. By the end of 2014 a total of 214 cases of CCHF had been confirmed in South Africa since the first case was recognized in 1981. The diagnostic tests involved the handling of 811 acute phase blood samples at BSL-2 or 3 level with PPE (disposable gown, gloves, laboratory spectacles and N95 masks) without infections or seroconversions being recorded in the diagnostic laboratory, where the personnel regularly handle such specimens. The equipment used included class II cabinets, bench centrifuges, PCR thermocyclers, electrophoresis tanks, gel documentation readers, ELISA plate washers and readers and fluorescence microscopes. Mouse inoculation and tissue harvesting were performed in class II cabinets and cages were held in a dedicated room with Hepa-filtered air supply and exhaust.

In contrast, the two laboratory infections reported above, occurred in clinical pathology laboratories in hospitals where CCHF is infrequently encountered so that an adequate state of awareness is more difficult to maintain (all information on South Africa; R. Swanepoel, personal communication).

In Turkey, laboratory services issued instructions on the taking and shipment of samples, and made the information widely available on a web page (www.thsk.gov.tr). Shipments were strictly controlled and out of necessity diagnostic assays were performed in BSL-2 laboratories. Samples had to be handled in class II biosafety cabinets using PPE (lab coat , gloves, googles and NP95 mask). [30]. Although a BSL-3 laboratory was finally opened in Ankara in 2012, it is not used for CCHFV diagnostics. At the time of drafting the present report there had been 9,787 clinical and laboratory confirmed cases of CCHF since 2003, and an estimated 90.000-100000 samples had been processed under BSL-2 conditions [60]. In some hospitals CCHF blood samples are handled on the open bench by HCW wearing gloves and N95 masks, but no goggles. (Z. Kocak Tufan and C. Bulut, Turkey, personal communication). Two case of LAI have been reported one due to a needlestick while drawing blood and one due to handling a blood sample without wearing gloves [60].

Laboratory acquired infections during research

In an incident in the Rostov-na-Donu laboratory in 1970, one of 4 staff members exposed to aerosols from a flask containing live virus that disintegrated in a centrifuge fell severely ill and died. In this instance an underlying chronic hepatocholecystis may have contributed to the fatal outcome [64].

In 1973, at the Institute for Epidemiology, Microbiology and Infectious Disease in Alma Ata (USSR, now Kasakhstan) a scientist preparing CCHFV antigen from suckling mouse brain using freon extraction, fell severely ill and seroconverted but recovered. It was concluded that mixing volatile Freon with the brain suspension may have caused formation of aerosols which were inhaled. As a consequence work with volatile substances such as freon was required to be performed in chemical cabinets only [65].

In 1981, a virologist died in Cairo, Egypt after mouth-pipetting a culture of an CCHFV isolate he had brought from Iraq (A. A. El-Sanousi, Egypt, personal communication).

At the Institute Pasteur de Dakar two accidents were linked to handling suckling mice inoculated with a diagnostic sample and a tick pool suspension: in 1998 a technician suffered a needle stick accident, and in 1993 a staff member in breach of regulations handled cages with infected mice on an open bench without wearing any mask. They both fell ill, but experienced mild, self limiting disease. Also in 1993, another technician was exposed to aerosols while preparing sucrose acetone antigen from infected suckling mouse brain since not all equipment was held in a laminar flow cabinet or in a BSL-3 laboratory. Again the disease was self-limiting. A BSL-3 laboratory was built in Dakar in 1999. Henceforth, infected mouse cages were held in a special laboratory and brain material was treated with beta propiolactone prior to use as antigen in routine ELISA for IgM/G antibody detection and immune ascitic fluid production in mice.

In 1999 a technician inflicted an abrasion on her hand with a needle during a CCHFV baby mouse brain passage procedure in the National Center of Infectious and Parasitic Diseases laboratory in Sofia, in Bulgaria. However, she was vaccinated with the Bulgarian CCHFV vaccine and presented with benign febrile illness only. In 2010, a Turkish laboratory worker in a university laboratory inadvertently poured a flask with a 10^{th} passage CCHFV culture down the front of her labcoat but was not infected nor seroconverted (Aykut Ozkul, Turkey, personal communication).

Inactivation

Several publications have shown that chaotropic guanidine-isothiocyanate in commercial nucleic acid extraction buffers efficiently inactivates most enveloped viral agents including

231 pox-, alpha-, bunya-, flavi- and filoviruses [66-68].

232 Non-treated acute phase serum samples of CCHF patients stored at $+4^0$C remain real time-PCR
233 positive for up to 30 days but the infectivity of these samples was not verified (A Kubar,
234 Turkey, personal communication). For serological analysis diagnostic laboratories in Turkey
235 and South East Europe use thermal inactivation of serum at 56°C for 30 min or even 45 min
236 although it was concluded in one study that 60°C for 60 min is more effective for CCHFV [69].
237 In experiments recently performed in the South African laboratory to clearly analyse the
238 conditions needed to inactivate CCHFV, CCHFV (strain SPU4/81) culture fluid with a titre of 1 x
239 $10^{7.6}$ $TCID_{50}$/ml was incubated at 56°C and 60°C for 15, 30, 45 and 60 minutes and then
240 inoculated into Vero E6 cell cultures. In all instances virus growth was not detected. To show
241 that the results were not due to the detection limit of the TCID assay at 1 x $10^{1.5}$ $TCID_{50}$/ml,
242 the inactivated suspensions were also inoculated intracerebraly into suckling mice (NIH strain)
243 and all mice survived, even those inoculated with virus inactivated at 56°C for only 15 minutes
244 (Figure 1). The experiments confirm that heat inactivation at 56°C/30 min used as a standard
245 in Turkish (national guideline) and many other laboratories in south-eastern Europe is
246 adequate for destruction of infectivity, and explains why LAI have not been reported from
247 these diagnostic laboratories.

248

249 **Biosafety regulations**

250 The UN Convention on the Prohibition of the Development, Production and Stockpiling of
251 Bacteriological (Biological) and Toxin weapons and on their Destruction (BTWC) as
252 promulgated in 1972 imposed requirements on member states (party to the convention) for
253 acquiring, holding, stockpiling, working with or disposing of certain pathogens (the list
254 includes CCHFV) at specified biosafety levels, but BTWC lacked an organization or mechanisms

to monitor and enforce compliance. Consequently, UN Security Council Resolution 1540 was passed in 2004 to enforce domestic compliance on states parties as well as non-state actors through a 1540 committee. Purely diagnostic procedures and laboratories are exempted. It should be noted that documents such as the Laboratory Safety Manual [WHO, 2004], the Biosafety in Microbiological and Biomedical Laboratories manual [56], and the European CEN Workshop Agreement 15793 [CWA 15793, 2011] only make recommendations on biosafety, and do not impose legal requirements. Each country must promulgate its own biosafety legislation and regulations, and many have not yet done so. Consequently, there is wide divergence in the biosafety levels prescribed for handling CCHFV as some countries attempt to reconcile disease endemicity with laboratory capacity.

In a recent survey of laboratories in 28 countries that are members of the European Network for Diagnostics of Imported Viral Diseases (ENIVD), it was found that 7 countries sent diagnostic samples for CCHF to reference centres elsewhere, 5 tested samples in BSL-2 laboratories, 10 in BSL-3 laboratories and 6 in BSL-4 laboratories. Of 11 laboratories performing virus isolation and propagation, 6 did so in BSL-4 facilities and 5 in lower-grade facilities [70]. Enquiries made for purposes of the present review revealed that in Slovenia, Turkey and Senegal CCHFV diagnostic samples were handled at BSL-2 for years before a BSL-3 laboratory was finally available for research. In many other countries including Turkey, Kosovo, Albania, Bulgaria diagnostics are still performed at BSL-2. Even in the US diagnostic samples are not handled in BSL-4 but in BSL-2 laboratories until the presence of CCHFV has been confirmed. In most non endemic countries diagnostic investigations however are conducted in BSL-4 facilities. All countries tend to use higher grade facilities for research (Table 1).

Discussion

279 In non-endemic countries that coincidentally tend to be better resourced and can afford
280 sophisticated laboratories, CCHFV is classed and handled as a hazard group 4 agent (Table 1).
281 Agents in this group cause severe disease, are a serious hazard to staff, are likely to spread to
282 the community and there is no effective prophylaxis or treatment. In contrast, most endemic
283 countries have perforce had to perform diagnostic tests under BSL-2 or 3 conditions, using
284 appropriate PPE and laboratory practices. In particular, Turkey and several of the Balkan
285 countries have processed large numbers of specimens without experiencing any LAI over
286 many years. Although virological and seroepidemiological studies indicate that strains of virus
287 circulating in the region may have reduced virulence, this alone does not account for the lack
288 of observed LAI since monitoring for seroconversion confirms that transmission to HCW is rare.
289 The present survey was performed to collect information on LAI in hospitals, and diagnostic
290 and research laboratories. Only a few were identified. Such infections as have been reported
291 in BSL-2 diagnostic laboratories almost invariably result from breaches of biosafety practise.
292 Handling samples without gloves or mouth pipetting used in the initial isolations of CCHFV in
293 the 1950s are no longer acceptable. Lessons have been learned from exposure to droplets in
294 research settings, and in particular centrifuge buckets should be fitted with biosafety seals
295 (clip on lids), and hazardous procedures should be performed in biosafety cabinets [71].
296 Outside of cabinets, culture flasks should be carried in sealed boxes, lids should be used on
297 ELISA and culture plates during incubation, and film seals used for reading of plates. Sera
298 should be heat-inactivated at 56°C/30 min before performing antibody tests.
299 Safety can be increased by wearing PPE commonly used in BSL-3 laboratories (face shield
300 instead of goggles), without necessarily having to rely on positive pressure respirators.
301 Accidental spillage of infected material unfortunately remains a possibility, but need not
302 necessarily have a serious outcome as exemplified by the spill onto a Turkish laboratory

worker. Animal inoculation procedures should preferably be avoided in diagnostic laboratories that do not have BSL-3 or -4 facilities. For BSL-3 laboratories measures as implemented in Dakar are advisable.

There is however an ongoing debate on aerosol transmission of CCHFV in clinical settings There are only few reports describing the infection of close relatives of CCHFV patients, and these lack conclusive evidence of aerosol transmission [72,73]. On the contrary none of a cohort of 132 relatives staying with or visiting 88 CCHF patients of whom two patients died at the Cumhuriyet University Hospital in Turkey, developed any symptoms nor seroconverted despite the fact that many did not comply with protective measures [74]. The study indicates that CCHF is not easily spread between humans and into the community.

Although multiple-case incidents of nosocomial infection have been reported (Mauretania, Sudan, Pakistan [4]) there is no evidence for aerosol transmission in CCHF, and spread of infection was generally postulated to result from direct contact with body fluids or droplets of severely ill patients, percutaneous injuries and non compliance with basic infection control precautions.

A recent review of possible aerosol (1-5µm) or droplet (5-10µm) transmission through coughing and vomiting in Ebola virus disease, concludes that there are no epidemiological data to support a large role for this mode of transmission, and that respiratory transmission (aerosol generation in the lung, exhalation and transmission by inhalation) does not occur [75], and the same appears to apply to what is currently known about CCHF transmission. In contrast aerosol transmission is well documented for smallpox virus and was conclusively shown by retrospective smoke experiments after isolated patients caused nosocomial transmission in Meschede in Germany [76].

However if actively generated, aerosols are indeed very likely to increase transmission, as

recently described in a clinical setting due to the use of a compression inhaler to apply mucolytics and broncholytics to a CCHF patient while only surgical masks were used by HCW [77]. In a most recent report 2 HCW suffered an infection probably while using bag-valve-mask ventilation, or performing bronchoscopies on an infected patient [54]. The obvious conclusion is to use fitted N95 masks if inhalation devices are used or aerosols might be actively generated in any other way. On the other hand, care has to be taken when using this type of masks, as unpublished data from Public Health England (Nigel Silman, UK, personal communication) show that the filter of N95 masks should not be used for more than 2 hours as humidity trapped in the mask will bridge the filter, thus negating its efficiency.

In conclusion, diagnostic tests have been performed safely at BSL-2 level for many years in CCHF endemic countries that could not otherwise cope with demand. We therefore recommend that regulating authorities should revise biosafety requirements for CCHF diagnostic procedures to allow the required tests to be performed under enhanced BSL-2 conditions with appropriate biosafety laboratory equipment and PPE used according to standardized protocols in the affected countries (see box 1). In this respect we'd like to point out that class I cabinets which draw air away from the operator are preferable to class II cabinets which provide a sterile working area through creating a laminar flow. Organizations such as the Centres for Disease Control and Prevention, USA, the National Institutes for Health, USA, the World Health Organization, and the European Committee for Standardization, should revise international recommendations accordingly. Technical advances arising from the successful deployment of mobile BSL-3 laboratories in the West African outbreak of Ebola disease [78-81] should be exploited to derive cost-effective improvements to diagnostic laboratories in the CCHF endemic countries. In particular, the use of flexible-walled or hard plastic glove boxes for extraction of nucleic acids and inactivation of sera would greatly

improve laboratory safety. The evidence on LAI and LAI outcome, transmissibility and CFRs should merit to discuss the possibility of relaxing biosafety standards for research on CCHFV, and the graded application of isolation precautions in the treatment of patients according to clinical status should be codified.

Acknowledgements

Funding was received through CCH Fever Network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Program of the 7th Framework Program (Grant agreement no. 260427) (http://www.cch-fever.eu/).

Disclaimer

The views expressed by state employed American co-authors are their personal views, and do not necessarily represent the views of the US government agencies they work for.

Table1. CCHFV hzard groups and biosafety levels

Country	Endemic	Hazard group	Biosafety level of CCHFV diagnostics	Biosafety level of CCHFV research
South-Africa	+	2	BSL-2 1980-2004 BSL-3 since 2004	BSL 4
Slovenia	-	4	BSL-2 1995-2004 BSL-3 since 2004	BSL 3 since 2004
Albania	+	2	BSL-2	BSL-3
Kosovo	+	2	BSL-2	BSL-2
Greece	+	4	BSL-2 1975-1987	BSL 3 glovebox introduced in 1987
Bulgaria	+	3	BSL-2	BSL-3
Serbia	+	?	BSL-2	----
Turkey	+	2	BSL-2	BSL-3 since 2012
Kazakhstan	+	4	BSL-3	BSL-4
Georgia	+	4	BSL-3	BSL-4
Iran	+	3	BSL-2 glovebox	
Senegal	+	3	BSL-2 glovebox 1990-1999 BSL-3 2000-2015	BSL 3
Germany	-	4	BSL-4	BSL 4
Sweden	-	4	BSL 4	BSL 4
United Kingdom	-	4	BSL 4	BSL 4
France	-	4	BSL 4	BSL 4
United States	-	4	BSL-3	BSL 4

376 Box 1
377

Recommendations for working with CCHFV 378
379

Primary containment
BSL-2 laboratory
Class I / Class II biosafety cabinet*

PPE
Labcoat
Gloves
Goggles / Face-shield
N95 mask

Additional Procedures
Thermal inactivation of samples at 56°C/30min
Guanidin-thiocyonate based nucleic acid extraction
Seal ELISA plates with transparent film bevor removing from biosafety cabinet
Use centrifugation buckets with clipp on lids, open buckets in biosafety cabinet only.

*. It is recommended to switch to class I cabinets if possible.

References

1. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M: **Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity**. *Antiviral Research* 2013, **100**:159-189.
2. Ince Y, Yasa C, Metin M, Sonmez M, Meram E, Benkli B, Ergonul O: **Crimean-Congo hemorrhagic fever infections reported by ProMED**. *International Journal of Infectious Diseases* 2014, **26**:44-46.
3. Larichev. V: **Current Situation in CCHFV Epidemiology in Russia**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
4. Tarantola A, Ergonul O, Tattevin P: *Estimates and prevention of Crimean Congo hemorrhagic fever risks for health care workers.* Edited by Ergonul O, Whitehouse C, Dordrecht N: Springer; 2007.
5. Hoogstraal H: **The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa**. *J Med Entomol* 1979, **15**:307-417.
6. Lvov DK: **Arboviral zoonoses of northern Eurasia (Eastern Europe and the Commonwealth of Independent States)**. In *Handbook of Zoonoses,* . Edited by Beran GW: CRC Press, Boca Rotan, Florida.; 1994:237-260.
7. Samudzi RR, Leman PA, Paweska JT, Swanepoel R, Burt FJ: **Bacterial expression of Crimean-Congo hemorrhagic fever virus nucleoprotein and its evaluation as a diagnostic reagent in an indirect ELISA**. *J Virol Methods* 2012, **179**:70-76.
8. Williams RJ, Al-Busaidy S, Mehta FR, Maupin GO, Wagoner KD, Al-Awaidy S, Suleiman AJ, Khan AS, Peters CJ, Ksiazek TG: **Crimean-congo haemorrhagic fever: a seroepidemiological and tick survey in the Sultanate of Oman**. *Trop Med Int Health* 2000, **5**:99-106.
9. Duh D, Saksida A, Petrovec M, Ahmeti S, Dedushaj I, Panning M, Drosten C, Avsic-Zupanc T: **Viral load as predictor of Crimean-Congo hemorrhagic fever outcome**. *Emerg Infect Dis* 2007, **13**:1769-1772.
10. Burt FJ: **Current Situation in CCHFV Epidemiology in South Africa**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*
. Edited by. Thessaloniki; 2015.
11. Humoli. I DI: **Current Situation in CCHFV Epidemiology in Kosovo**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
12. Sadegh C: **Current Situation in CCHFV Epidemiology in Iran**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
13. Christova I: **Current Situation in CCHFV Epidemiology in Bulgaria**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
14. Korokluoglou G: **Current Situation in CCHFV Epidemiology in Turkey**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
15. Bodur H, Akinci E, Ascioglu S, Onguru P, Uyar Y: **Subclinical Infections with Crimean-Congo Hemorrhagic Fever Virus, Turkey**. *Emerging Infectious Diseases* 2012, **18**:640-642.
16. Gunes T, Engin A, Poyraz O, Elaldi N, Kaya S, Dokmetas I, Bakir M, Cinar Z: **Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey**. *Emerg Infect Dis* 2009, **15**:461-464.
17. Tezer H, Sucakli IA, Sayli TR, Celikel E, Yakut I, Kara A, Tunc B, Ergonul O: **Crimean-Congo hemorrhagic fever in children**. *Journal of Clinical Virology* 2010, **48**:184-186.

18. Burt FJ, Swanepoel R, Braack LE: **Enzyme-linked immunosorbent assays for the detection of antibody to Crimean-Congo haemorrhagic fever virus in the sera of livestock and wild vertebrates**. *Epidemiol Infect* 1993, **111**:547-557.
19. Shepherd AJ, Swanepoel R, Leman PA, Shepherd SP: **Field and laboratory investigation of Crimean-Congo haemorrhagic fever virus (Nairovirus, family Bunyaviridae) infection in birds**. *Trans R Soc Trop Med Hyg* 1987, **81**:1004-1007.
20. Shepherd AJ, Swanepoel R, Shepherd SP, McGillivray GM, Searle LA: **Antibody to Crimean-Congo hemorrhagic fever virus in wild mammals from southern Africa**. *Am J Trop Med Hyg* 1987, **36**:133-142.
21. Mourya DT, Yadav PD, Shete A, Majumdar TD, Kanani A, Kapadia D, Chandra V, Kachhiapatel AJ, Joshi PT, Upadhyay KJ, et al.: **Serosurvey of Crimean-Congo Hemorrhagic Fever Virus in Domestic Animals, Gujarat, India, 2013**. *Vector-Borne and Zoonotic Diseases* 2014, **14**:690-692.
22. Fajs L, Humolli I, Saksida A, Knap N, Jelovsek M, Korva M, Dedushaj I, Avsic-Zupanc T: **Prevalence of Crimean-Congo hemorrhagic fever virus in healthy population, livestock and ticks in Kosovo**. *PLoS One* 2014, **9**:e110982.
23. Mertens. M VZ, Farkas. R, Donnet. F, Comtet. L, Ben Mechlia. M, Tordo. N, Groschup. H: **CCHFV – The first line of protection is understanding**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
24. Midilli K, Gargili A, Ergonul O, Elevli M, Ergin S, Turan N, Sengoz G, Ozturk R, Bakar M: **The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey**. *Bmc Infectious Diseases* 2009, **9**.
25. Elevli M, Ozkul AA, Civilibal M, Midilli K, Gargili A, Duru NS: **A newly identified Crimean-Congo hemorrhagic fever virus strain in Turkey**. *International Journal of Infectious Diseases* 2010, **14**:E213-E216.
26. Ozkaya E, Dincer E, Carhan A, Uyar Y, Ertek M, Whitehouse CA, Ozkul A: **Molecular epidemiology of Crimean-Congo hemorrhagic fever virus in Turkey: Occurrence of local topotype**. *Virus Research* 2010, **149**:64-70.
27. Papadopoulos O, Koptopoulos G: *Crimean-Congo hemorrhagic fever (CCHF) in Greece: Isolation of the virus from Rhipicephalus bursa ticks and a preliminary serological survey.* . Edited by Vesenjak-Hirjan J, Porterfield J: Gustav Fisher Verlag, Stuttgart. ; 1980.
28. Papa A, Chaligiannis I, Kontana N, Sourba T, Tsioka K, Tsatsaris A, Sotiraki S: **A novel AP92-like Crimean-Congo hemorrhagic fever virus strain, Greece**. *Ticks and Tick-Borne Diseases* 2014, **5**:590-593.
29. Bino. S: **Current Situation in CCHFV Epidemiology in Albania**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
30. Uyar Y, Carhan A, Albayrak N, Altas AB: **Evaluation of PCR and ELISA-IgM results in the laboratory diagnosis of Crimean-Congo Haemorrhagic Fever cases in 2008 in Turkey**. *Mikrobiyoloji Bulteni* 2010, **44**:57-64.
31. Vaneeden PJ, Vaneeden SF, Joubert JR, King JB, Vandewal BW, Michell WL: **A Nosocomial Outbreak of Crimean-Congo Hemorrhagic-Fever at Tygerberg-Hospital .2. Management of Patients**. *South African Medical Journal* 1985, **68**:718-721.
32. Shepherd AJ, Swanepoel R, Shepherd SP, Leman PA, Blackburn NK, Hallett AF: **A Nosocomial Outbreak of Crimean-Congo Hemorrhagic-Fever at Tygerberg-Hospital .5. Virological and Serological Observations**. *South African Medical Journal* 1985, **68**:733-736.

33. Joubert JR, King JB, Rossouw DJ, Cooper R: **A Nosocomial Outbreak of Crimean-Congo Hemorrhagic-Fever at Tygerberg-Hospital .3. Clinical Pathology and Pathogenesis**. *South African Medical Journal* 1985, **68**:722-728.
34. Vaneeden PJ, Joubert JR, Vandewal BW, King JB, Dekock A, Groenewald JH: **A Nosocomial Outbreak of Crimean-Congo Hemorrhagic-Fever at Tygerberg-Hospital .1. Clinical-Features**. *South African Medical Journal* 1985, **68**:711-717.
35. Vandewal BW, Joubert JR, Vaneeden PJ, King JB: **A Nosocomial Outbreak of Crimean-Congo Hemorrhagic-Fever at Tygerberg-Hospital .4. Preventive and Prophylactic Measures**. *South African Medical Journal* 1985, **68**:729-732.
36. Nabeth P, Cheikh DO, Lo B, Faye O, Vall IOM, Niang M, Wague B, Diop D, Diallo M, Diallo B, et al.: **Crimiean-Congo hemorrhagic fever, Mauritania**. *Emerging Infectious Diseases* 2004, **10**:2143-2149.
37. Elata AT, Karsany MS, Elageb RM, Hussain MA, Eltom KH, Elbashir MI, Aradaib IE: **A nosocomial transmission of crimean-congo hemorrhagic fever to an attending physician in north kordufan, Sudan**. *Virology Journal* 2011, **8**.
38. Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E, Pavlidou V, Velo E, Cahani G, Hajdini M, Pilaca A, et al.: **Crimean-Congo hemorrhagic fever in Albania, 2001**. *European Journal of Clinical Microbiology & Infectious Diseases* 2002, **21**:603-606.
39. Harxhi A, Pilaca A, Delia Z, Pano K, Rezza G: **Crimean-Congo hemorrhagic fever: a case of nosocomial transmission**. *Infection* 2005, **33**:295-296.
40. Papa A, Bozovi B, Pavlidou V, Papadimitriou E, Pelemis M, Antoniadis A: **Genetic detection and isolation of Crimean-Congo hemorrhagic fever virus, Kosovo, Yugoslavia**. *Emerging Infectious Diseases* 2002, **8**:852-854.
41. Papa A, Christova I, Papadimitriou E, Antoniadis A: **Crimean-Congo hemorrhagic fever in Bulgaria**. *Emerging Infectious Diseases* 2004, **10**:1465-1467.
42. Kunchev A, Kojouharova M: **Probable cases of Crimean-Congo-haemorrhagic fever in Bulgaria: a preliminary report**. *Euro Surveill* 2008, **13**.
43. Gurbuz Y, Sencan I, Ozturk B, Tutuncu E: **A case of nosocomial transmission of Crimean-Congo hemorrhagic fever from patient to patient**. *Int J Infect Dis* 2009, **13**:e105-107.
44. Celikbas AK, Dokuzoguz B, Baykam N, Gok SE, Eroglu MN, Midilli K, Zeller H, Ergonul O: **Crimean-Congo Hemorrhagic Fever among Health Care Workers, Turkey**. *Emerging Infectious Diseases* 2014, **20**:477-479.
45. Naderi H, Sheybani F, Bojdi A, Khosravi N, Mostafavi I: **Short Report: Fatal Nosocomial Spread of Crimean-Congo Hemorrhagic Fever with Very Short Incubation Period**. *American Journal of Tropical Medicine and Hygiene* 2013, **88**:469-471.
46. Chinikar S, Shayesteh M, Khakifirouz S, Jalali T, Varaie FSR, Rafigh M, Mostafavi E, Shah-Hosseini N: **Nosocomial infection of Crimean-Congo haemorrhagic fever in eastern Iran: Case report**. *Travel Medicine and Infectious Disease* 2013, **11**:252-255.
47. Mardani M, Keshtkar-Jahromi M, Ataie B, Adibi P: **Short Report: Crimean-Congo Hemorrhagic Fever Virus as a Nosocomial Pathogen in Iran**. *American Journal of Tropical Medicine and Hygiene* 2009, **81**:675-678.
48. Suleiman MN, Muscat-Baron JM, Harries JR, Satti AG, Platt GS, Bowen ET, Simpson DI: **Congo/Crimean haemorrhagic fever in Dubai. An outbreak at the Rashid Hospital**. *Lancet* 1980, **2**:939-941.
49. Hasan Z, Mahmood F, Jamil B, Atkinson B, Mohammed M, Samreen A, Altaf L, Moatter T, Hewson R: **Crimean-Congo hemorrhagic fever nosocomial infection in a immunosuppressed patient, Pakistan: Case report and virological investigation**. *Journal of Medical Virology* 2013, **85**:501-504.

50. Burney MI, Ghafoor A, Saleen M, Webb PA, Casals J: **Nosocomial Outbreak of Viral Hemorrhagic-Fever Caused by Crimean Hemorrhagic-Fever Congo Virus in Pakistan, January 1976**. *American Journal of Tropical Medicine and Hygiene* 1980, **29**:941-947.
51. Yadav PD, Cherian SS, Zawar D, Kokate P, Gunjikar R, Jadhav S, Mishra AC, Mourya DT: **Genetic characterization and molecular clock analyses of the Crimean-Congo hemorrhagic fever virus from human and ticks in India, 2010-2011**. *Infection Genetics and Evolution* 2013, **14**:223-231.
52. ProMED-mail.: **Crimean-Congo hem. fever - Tajikistan: (TC).** . *ProMED-mail* **2009;15 Aug: 20090815.2898.** .
53. ProMED-mail.: **Crimean-Congo hem. Fever - Kazakhstan: (SK)**. *ProMED-mail* **2009;15 Jul: 20090715.2529.** .
54. Conger NG, Paolino KM, Osborn EC, Rusnak JM, Gunther S, Pool J, Rollin PE, Allan PF, Schmidt-Chanasit J, Rieger T, et al.: **Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009**. *Emerg Infect Dis* 2015, **21**:23-31.
55. Cevik MA, Erbay A, Bodur H, Eren SS, Akinci E, Sener K, Onguru P, Kubar A: **Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever**. *Clin Infect Dis* 2007, **45**:e96-100.
56. Ergonul O, Zeller H, Celikbas A, Dokuzoguz B: **The lack of Crimean-Congo hemorrhagic fever virus antibodies in healthcare workers in an endemic region**. *Int J Infect Dis* 2007, **11**:48-51.
57. Akinci E, Öngürü P, Tanrici A, Uyar Y, Eren S, Bodur H: **Hemorrhagic Fever Seroprevalence in Healthcare Workers**. *FLORA The Journal of Infectious and Clinical Microbiology* **14**:94-96.
58. Tuna. N KO: **Current CCHFV transmission with contaminated mask: Case Report**. In *1st International Conference on Crimean-Congo Hemorrhagic Fever*. Edited by. Thessaloniki; 2015.
59. Mardani M, Rahnavardi M, Rajaeinejad M, Naini KH, Chinikar S, Pourmalek F, Rostami M, Shahri MH: **Crimean-Congo hemorrhagic fever among health care workers in Iran: A seroprevalence study in two endemic regions**. *American Journal of Tropical Medicine and Hygiene* 2007, **76**:443-445.
60. Leblebicioglu H, Sunbul M, Guner R, Bodur H, Bulut C, Duygu F, Elaldi N, Senturk GC, Ozkurt Z, Yilmaz G, et al.: **Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002-2014: a multicentre retrospective cross-sectional study**. *Clinical Microbiology and Infection* 2016, **22**.
61. Gozel MG, Dokmetas I, Oztop AY, Engin A, Elaldi N, Bakir M: **Recommended precaution procedures protect healthcare workers from Crimean-Congo hemorrhagic fever virus**. *International Journal of Infectious Diseases* 2013, **17**:E1046-E1050.
62. Bulut. C, Yilmaz. GR., Karako. E, Onde. U, Kocak Tufan. Z, AP D: **Risk of Crimean-Congo haemorrhagic fever among healthcare workers** *Clinical Microbiology and Infection Special Issue: Abstracts of the 19th ECCMID* 2009, **15**:S654.
63. Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP, McGillivray GM, Erasmus MJ, Searle LA, Gill DE: **Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa**. *Am J Trop Med Hyg* 1987, **36**:120-132.
64. Gaidamovich SY, Butenko AM, Leschinskaya HV: **Human Laboratory Acquired Arbo-, Arena-, and Hantavirus Infections**. *Journal of the American Biological Safety Association* 2000, **5**.

65. Karimov SK, Kiryushchenko TV, Reformatskaya AF, Suleimenova GS: **A CASE OF LABORATORY INFECTION WITH THE CRIMEAN HEMORRHAGIC FEVER VIRUS**. *Zhurnal Mikrobiologii Epidemiologii i Immunobiologii* 1975, **5**:136-137.
66. Blow JA, Dohm DJ, Negley DL, Mores CN: **Virus inactivation by nucleic acid extraction reagents**. *Journal of Virological Methods* 2004, **119**:195-198.
67. Vinner L, Fomsgaard A: **Inactivation of orthopoxvirus for diagnostic PCR analysis**. *J Virol Methods* 2007, **146**:401-404.
68. Smither SJ, Weller SA, Phelps A, Eastaugh L, Ngugi S, O'Brien LM, Steward J, Lonsdale SG, Lever MS: **Buffer AVL Alone Does Not Inactivate Ebola Virus in a Representative Clinical Sample Type**. *J Clin Microbiol* 2015, **53**:3148-3154.
69. Mitchell SW, Mccormick JB: **Physicochemical Inactivation of Lassa, Ebola, and Marburg Viruses and Effect on Clinical Laboratory Analyses**. *Journal of Clinical Microbiology* 1984, **20**:486-489.
70. Fernandez-Garcia MD, Negredo A, Papa A, Donoso-Mantke O, Niedrig M, Zeller H, Tenorio A, Franco L, Enivd M: **European survey on laboratory preparedness, response and diagnostic capacity for Crimean-Congo haemorrhagic fever, 2012**. *Euro Surveill* 2014, **19**.
71. Weidmann M: *Learning from a history of laboratory accidents*. Edited by Weidmann M, EIschner M, Silman N, Butaye P: Wiley Blackwell, ; 2012.
72. Saijo M, Tang Q, Shimayi B, Han L, Zhang Y, Asiguma M, Tianshu D, Maeda A, Kurane I, Morikawa S: **Possible horizontal transmission of Crimean-Congo hemorrhagic fever virus from a mother to her child**. *Japanese Journal of Infectious Diseases* 2004, **57**:55-57.
73. Tezer H, Tavil B, Sucakli IA, Korukluoglu G, Uyar Y, Dincer E, Tunc B, Ozkul A: **Concurrent Crimean-Congo Hemorrhagic Fever and Visceral Leishmaniasis in a Turkish Girl**. *Vector-Borne and Zoonotic Diseases* 2011, **11**:743-745.
74. Gozel MG, Bakir M, Oztop AY, Engin A, Dokmetas I, Elaldi N: **Investigation of Crimean-Congo Hemorrhagic Fever Virus Transmission from Patients to Relatives: A Prospective Contact Tracing Study**. *American Journal of Tropical Medicine and Hygiene* 2014, **90**:160-162.
75. Osterholm MT, Moore KA, Kelley NS, Brosseau LM, Wong G, Murphy FA, Peters CJ, LeDuc JW, Russell PK, Van Herp M, et al.: **Correction for Osterholm et al., Transmission of Ebola Viruses: What We Know and What We Do Not Know**. *MBio* 2015, **6**:e01154.
76. Wehrle PF, Posch J, Richter KH, Henderso.Da: **Airborne Outbreak of Smallpox in a German Hospital and Its Significance with Respect to Other Recent Outbreaks in Europe**. *Bulletin of the World Health Organization* 1970, **43**:669-&.
77. Pshenichnaya NY, Nenadskaya SA: **Probable Crimean-Congo hemorrhagic fever virus transmission occurred after aerosol-generating medical procedures in Russia: nosocomial cluster**. *Int J Infect Dis* 2015, **33C**:120-122.
78. Chen Z, Chang G, Zhang W, Chen Y, Wang X, Yang R, Liu C: **Mobile laboratory in Sierra Leone during outbreak of Ebola: practices and implications**. *Sci China Life Sci* 2015, **58**:918-921.
79. Inglis TJ: **Adapting the mobile laboratory to the changing needs of the Ebolavirus epidemic**. *J Med Microbiol* 2015, **64**:587-591.
80. Wolfel R, Stoecker K, Fleischmann E, Gramsamer B, Wagner M, Molkenthin P, Di Caro A, Gunther S, Ibrahim S, Genzel GH, et al.: **Mobile diagnostics in outbreak response, not only for Ebola: a blueprint for a modular and robust field laboratory**. *Euro Surveill* 2015, **20**.

81. Faye O, Faye O, Soropogui B, Patel P, El Wahed AA, Loucoubar C, Fall G, Kiory D, Magassouba N, Keita S, et al.: **Development and deployment of a rapid recombinase polymerase amplification Ebola virus detection assay in Guinea in 2015**. *Euro Surveill* 2015, **20**.

Figure legend

Figure 1. Percent survival of suckling mice i.c. injected with CCHFV-FBS mix (1 x $10^{7.3}$ $TCID_{50}$/ml). Dark grey dots: Untreated CCHFV-FBS mix (positive control, n=9 mice). Grey squares CCHFV-FBS mix treated at RT/15min (n=4), Grey triangles: CCHFV-FBS mix treated at RT/60min (n=9). White circles: CCHFV-FBS mix treated at 56°C for 15/30/45/60 minutes (n= 8/8/8/5), White triangles: CCHFV-FBS mix treated at 60°C for 15/30/45/60 minutes (n= 10/8/10/10). Please note that due to overlay only on line with white circles and one line with white triangles can be seen on the graph.